Northwest Biotherapeutics (OTCMKTS:NWBO) Shares Gap Up - What's Next?

Key Points

• Shares gapped up — the stock opened at $0.3355 after closing at $0.32 and last traded at $0.3270 on volume of 2,897,317 shares.
• The company trades above its 50‑day and 200‑day averages (~$0.24 and $0.25), has a market cap of $504.17M, a negative PE, and reported a quarterly loss of ($18.22) EPS on just $0.2M in revenue.
• Northwest Biotherapeutics is a clinical‑stage biotech developing personalized dendritic‑cell immunotherapies, with lead candidate DCVax‑L in a global Phase III trial for glioblastoma multiforme.

Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO - Get Free Report)'s share price gapped up prior to trading on Tuesday . The stock had previously closed at $0.32, but opened at $0.3355. Northwest Biotherapeutics shares last traded at $0.3270, with a volume of 2,897,317 shares trading hands.

Northwest Biotherapeutics Stock Performance

The stock's 50-day moving average is $0.24 and its two-hundred day moving average is $0.25. The stock has a market cap of $504.17 million, a PE ratio of -0.02 and a beta of -0.86.

Northwest Biotherapeutics (OTCMKTS:NWBO - Get Free Report) last released its quarterly earnings results on Friday, November 14th. The biotechnology company reported ($18.22) EPS for the quarter. The business had revenue of $0.20 million during the quarter.

About Northwest Biotherapeutics

Northwest Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of personalized dendritic cell immunotherapies for the treatment of cancer. The company's proprietary platform harnesses patient-derived dendritic cells to present tumor-specific antigens and stimulate a targeted immune response. By tailoring each vaccine to the individual patient's tumor profile, the approach aims to improve outcomes and reduce off-target toxicity associated with conventional therapies.

The company's lead candidate, DCVax®-L, is designed for patients with newly diagnosed or recurrent glioblastoma multiforme (GBM) and has advanced through a global Phase III clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.